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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER9Cardiac Uses of Phosphodiesterase-5 InhibitorsBryan G. Schwartz, Laurence A. Levine, Gary Comstock, Vera J. Stecher, Robert A. Kloner
Phosphodiesterase-5 inhibitors (PDE5Is) improve erectile function by enhancing nitric oxide
availability in the penis resulting in vasodilation and increased blood flow. PDE5Is may
benefit cardiovascular diseases as phosphodiesterase-5 is present in the pulmonary and
systemic vasculature and in hypertrophied myocardium. PDE5Is are approved for primary
pulmonary arterial hypertension and emerging evidence suggests that PDE5Is benefit patients
with congestive heart failure and secondary pulmonary hypertension. PDE5Is have
demonstrated benefit for patients with Raynaud’s phenomenon and may be useful for
preventing reperfusion injury. This review by Schwartz and colleagues presents the
pathophysiology and trial data regarding the use of PDE5Is for cardiac diseases.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY16Poor Outcomes for Balloon Angioplasty of Occluded Femoropopliteal StentsAtsushi Tosaka, Yoshimitsu Soga, Osamu Iida, Takayuki Ishihara, Keisuke Hirano, Kenji Suzuki,
Hiroyoshi Yokoi, Shinsuke Nanto, Masakiyo Nobuyoshi
A multicenter, retrospective study was performed to investigate the relationship between
angiographic patterns of femoropopliteal (FP) stent restenosis and clinical outcomes. A total
of 133 in-stent restenotic (ISR) lesions after FP artery stenting were classified as focal
(50 mm in length), diffuse (50 mm in length), or total occlusion with approximately equal
frequency. All patients were treated with balloon angioplasty. During follow-up, 50% of
patients with focal or diffuse ISR had recurrent ISR, but almost 90% of those with total
occlusion had recurrent ISR and these patients also had much higher rates of reocclusion and
worse clinical outcomes.
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26enal Function Improves in Most Patients
Following Implantation of Continuous Flow LVADsTal Hasin, Yan Topilsky, John A. Schirger, Zhuo Li, Yanjun Zhao, Barry A. Boilson, Alfredo L. Clavell,
Richard J. Rodeheffer, Robert P. Frantz, Brooks S. Edwards, Naveen L. Pereira, Lyle Joyce, Richard Daly,
Soon J. Park, Sudhir S. Kushwaha
Renal dysfunction prior to left ventricular assist device (LVAD) placement is frequent, but it
is not always clear if it is due to primary renal disease or poor perfusion. Hasin and colleagues
performed a retrospective single-center analysis of 83 consecutive patients implanted with a
HeartMate II continuous flow LVAD (Thoratec Corp., Pleasanton, California). Glomerular
filtration rate (GFR) significantly increased from admission to 1 month after LVAD
implantation and remained above pre-LVAD values at 3 and 6 months. Of the 51 patients
with GFR 60 ml/min/1.73 m2 before LVAD surviving at 1 month, 67% improved to a
FR 60 ml/min/1.73 m2. In most patients with end-stage heart failure considered forLVAD, renal dysfunction is reversible and likely related to poor renal perfusion.CLINICAL RESEARCH HEART RHYTHM DISORDERS37EP Study Not Useful for Risk Stratification in Brugada PatientsSilvia G. Priori, Maurizio Gasparini, Carlo Napolitano, Paolo Della Bella, Andrea Ghidini Ottonelli,
Biagio Sassone, Umberto Giordano, Carlo Pappone, Giosuè Mascioli, Guido Rossetti, Roberto De Nardis,
Mario Colombo
The PRELUDE (PRogrammed ELectrical stimUlation preDictive valUe) prospective registry
was designed to assess the utility of programmed electrical stimulation (PES) or other clinical
factors for predicting the risk of ventricular arrhythmias in patients with Brugada Syndrome
(BrS). Patients with a spontaneous or drug-induced type I electrocardiogram (ECG) and
without history of cardiac arrest were enrolled and underwent a standard protocol of PES
which induced ventricular tachyarrhythmias in 40% of patients. During follow-up, 14
arrhythmic events (4.5%) occurred. Arrhythmia inducibility during PES was not a predictor
of events at follow up (9 of 14 events occurred in noninducible patients). These data show
that ventricular tachycardia/ventricular fibrillation inducibility during PES does not identify
high-risk BrS patients while the presence of a spontaneous type I ECG, history of syncope,
ventricular effective refractory period 200 ms, and QRS-fragmentation seem useful to
dentify candidates for prophylactic implantable cardioverter-defibrillator.
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491-Adrenergic Receptor Polymorphism Predicts a Favorable Response
to Rate Control Therapy in Patients With AFBabar Parvez, Nagesh Chopra, Shane Rowan, Joseph C. Vaglio, Raafia Muhammad, Dan M. Roden,
Dawood Darbar
Parvez and colleagues evaluated the impact of clinical factors and 2 common 1-adrenergic
receptor (ADRB1) polymorphisms (Arg389Gly and Ser49Gly) on response to ventricular rate
control therapy in patients with atrial fibrillation (AF). A ‘responder’ displayed adequate
ventricular rate control based on the AFFIRM criteria. Multiple clinical variables (age,
gender, hypertension) failed to predict response to rate-control therapy. By contrast, variant
Arg389Gly was significantly associated with adequate rate control (odds ratio: 1.44). A
common ADRB1 polymorphism, which alters post-receptor signaling, may modulate the
response to rate control therapy in AF patients.Editorial Comment: Sharon Cresci, page 57CLINICAL RESEARCH CARDIAC SURGERY
60yocardial Redox State Predicts Early Outcomes After Cardiac Surgery,
Improved by Statin TreatmentCharalambos Antoniades, Michael Demosthenous, Svetlana Reilly, Marios Margaritis, Mei-Hua Zhang,
Alexios Antonopoulos, Kyriakoula Marinou, Keshav Nahar, Raja Jayaram, Dimitris Tousoulis,
Constantinos Bakogiannis, Rana Sayeed, Costas Triantafyllou, Nikolaos Koumallos, Costas Psarros,
Antigoni Miliou, Christodoulos Stefanadis, Keith M. Channon, Barbara Casadei
Antoniades and colleagues evaluated the role of the myocardial redox state as a predictor of
complications after cardiac surgery and the effect of statins on the myocardial redox state.
Myocardial superoxide anion (O2) and peroxynitrite (ONOO) and their enzymatic sources
were quantified from right atrial appendage (RAA) samples from 303 patients undergoing
cardiac surgery, and in 42 patients who were randomized to receive atorvastatin or placebo
before surgery. Atrial O2 and ONOO were independently associated with increased risk
f atrial fibrillation, the need for post-operative inotropic support, and the length of hospital
tay. Pre-operative atorvastatin treatment suppressed atrial nicotinamide adenine dinucleotide
hosphate (NADPH) oxidase activity and myocardial O2 and ONOO production, which
was confirmed with ex vivo studies. These findings suggest that inhibition of NADPH
oxidases may contribute to the beneficial effect of statins in patients undergoing cardiac
surgery.
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74imilar Relationships Between Blood Pressure and
CV Risk in Diabetics and NondiabeticsJosep Redon, Giuseppe Mancia, Peter Sleight, Helmut Schumacher, Peggy Gao, Janice Pogue, Robert Fagard,
Paolo Verdecchia, Michael Weber, Michael Böhm, Bryan Williams, Khalid Yusoff, Koon Teo, Salim Yusuf,
on behalf of the ONTARGET Investigators
Redon and associates reviewed data from the ONTARGET trial (ONgoing Telmisartan
Alone and in combination with Ramipril Global Endpoint Trial) to determine if the blood
pressure (BP) at which cardiovascular (CV) protection is achieved differs between diabetics
and nondiabetics. In the ONTARGET trial, over 25,000 subjects with very-high CV risk
were randomized to ramipril, telmisartan, or both. Compared to nondiabetics, diabetics had a
significantly higher risk. The relationship between BP and CV risk had a similar pattern in
diabetics and nondiabetics over a wide range of baseline and in-treatment BP values although
at the same SBP a higher risk was observed in diabetics. These results do not suggest that
optimal BP is lower in diabetics than nondiabetics.
